The aim of this study is to To investigate in an exploratory manner the efficacy of 50 mg
opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa
decarboxylase inhibitor (DDCI), in Parkinson's disease (PD) patients with end-of-dose motor
fluctuations and associated sleep disorders